Electrophysiological effects of SKF83959 on hippocampal CA1 pyramidal neurons: Potential mechanisms for the drug's neuroprotective effects

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Chu, Hong Yuan ^a   Gu, Qinhua ^a   Jin, Guo Zhang ^a   Hu, Guo Yuan ^a   Zhen, Xuechu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSIS; DRUG MECHANISM; ELECTROPHYSIOLOGY; HIPPOCAMPUS; MALE; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PYRAMIDAL NERVE CELL; RAT; VOLTAGE CLAMP;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; HIPPOCAMPUS; MEMBRANE POTENTIALS; NEURONS; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; PYRAMIDAL CELLS; RATS;

PARKINSONIA; RATTUS;

EID: 78049314663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013118     Document Type: Article

References (30)

1. 1 dopamine receptors in rat brain. J Neurochem 85: 378-386.
2. [35S]GTP-γ-S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40: 826-837.
3. Arnt J, Hyttel J, Sanchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213: 259-267.
4. Cools AR, Lubbers L, van Oosten RV, Andringa G (2002) SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacology 42: 237-245.
5. Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ (2003) Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 474: 137-140.
6. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, et al. (1995) Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl) 117: 275-286.
7. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995) The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology (Berl) 117: 287-297.
8. Zhen X, Goswami S, Friedman E (2005) The role of the phosphatidyinositollinked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 80: 597-601.
9. Andringa G, Stoof JC, Cools AR (1999) Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology 146: 328-334.
10. Zhang H, Ma L, Wang F, Chen J, Zhen X (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDAlesioned rat model of Parkinson's disease. Neuropharmacology 53: 125-133.
11. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, et al. (1999) Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93: 1483-1489.
12. 1 receptor dependent inhibition of glycogen synthase kinase-3β; and a receptor-independent anti-oxidative action. J Neurochem 104: 946-956.
13. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW (1998) Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death. Neurobiol Dis 5: 81-88.
14. Yu SP, Yeh CH, Sensi SL, Gwag BJ, Canzoniero LM, et al. (1997) Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 278: 114-117.
15. Pal S, Hartnett KA, Nerbonne JM, Levitan ES, Aizenman E (2003) Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J Neurosci 23: 4798-4802.
16. Chen XQ, Zhang J, Neumeyer JL, Jin GZ, Hu GY, et al. (2009) Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K + Channel: A Potential Mechanism for Their Neuroprotective Effects. PLoS ONE 4: e5811.
17. Chen MT, Morales M, Woodward DJ, Hoffer BJ, Janak PH (2001) In Vivo Extracellular Recording of Striatal Neurons in the Awake Rat Following Unilateral 6-Hydroxydopamine Lesions. Exp Neurol 171: 72-83.
18. Schultz W, Ungerstedt U (1978) Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp Brain Res 33: 159-171.
19. Kish LJ, Palmer MR, Gerhardt GA (1999) Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and -amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats. Brain Res 833: 58-70.
20. Wahl-Schott C, Biel M (2009) HCN channels: Structure, cellular regulation and physiological function. Cell Mol Life Sci 66: 470-494.
21. Rosenkranz JA, Johnston D (2006) Dopaminergic Regulation of Neuronal Excitability through Modulation of Ih in Layer V Entorhinal Cortex. J Neurosci 26: 3229-3244.
22. Lesage F, Lazdunski M (2000) Molecular and functional properties of two-poredomain potassium channels. Am J Physiol Renal Physiol 279: F793-801.
23. Baruscotti M, Bucchi A, DiFrancesco D (2005) Physiology and pharmacology of the cardiac pacemaker (''funny'') current. Pharmacology & Therapeutics 107: 59-79.
24. Magee JC (1998) Dendritic Hyperpolarization-Activated Currents Modify the Integrative Properties of Hippocampal CA1 Pyramidal Neurons. J Neurosci 18: 7613-7624.
25. Poolos NP, Migliore M, Johnston D (2002) Pharmacological upregulation of hchannels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 5: 767-774.
26. Bean BP (2007) The action potential in mammalian central neurons. Nat Rev Neurosci 8: 451-465.
27. Calabresi P, Mercuri N, Sancesario G, Bernardi G (1993) Electrophysiology of dopamine-denervated striatal neurons. Brain 116: 433-452.
28. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375.
29. Santoro B, Chen S, Luthi A, Pavlidis P, Shumyatsky GP, et al. (2000) Molecular and functional heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS. J Neurosci 20: 5264-5275.
30. Yu Y, Chen XQ, Cui YY, Hu GY (2007) Electrophysiological actions of cyclosporin A and tacrolimus on rat hippocampal CA1 pyramidal neurons. Acta Pharmacol Sin 28: 1891-1897.